Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07753226 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Name: A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors — clinical trial record (NCT07753226)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorSichuan Baili Pharmaceutical Co., Ltd.

Started2026-08-18

View on ClinicalTrials.gov ↗

Amendment history

2026-09-08

Study Status, Contacts/Locations v2

Recruitment opened

Start dateestimated 2026-08→confirmed 2026-08-18

Study sitesdetails revised at 1 of 1 site

2026-08-25

Study Status, Contacts/Locations v1

Study sitescontacts updated at 1 of 1 site

2026-08-04

Original filing

Sichuan Baili Pharmaceutical Co., Ltd.

135 trials monitored

See 14 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic breast cancer and other solid tumors.

Trial Details

NCT Number	NCT07753226
Lead Sponsor	Sichuan Baili Pharmaceutical Co., Ltd. Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions	Breast Cancer, Solid Tumor
Enrollment	39 participants
Start Date	2026-08-18
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-10